$SONN Sonnet BioTherapeutics Holdings, Inc., an oncology-focused biotechnology company, develops platform for biologic medicines of
single or bispecific action.
The company develops fully human albumin binding (FHAB) technology,
which utilizes human single chain antibodies fragment that binds to
and hitch-hikes on human serum albumin for transport to target tissues.
Its lead candidate includes SON-080, a human version of low dose Interleukin-6 (IL-6), which has completed Phase I trials for the treatment of patients with chemotherapy-induced peripheral neuropathy.
The company is also developing SON-081, a low dose IL-6 for the treatment of patients with diabetic peripheral neuropathy and is
under phase I trials;
SON-1010, a FHAB derived compound, which utilizes a human version
of Interleukin-12 (IL-12) is under pre-clinical trial,
as well as SON-1210, a bi-specific construct that combines FHAB
with
IL-12 and human Interleukin-15 for the treatment of solid tumor is
under pre-clinical trial.
In addition, it develops SON-2014,
a bi-specific combination of granulocyte-macrophage colony stimulating factor and Interleukin-18 for the treatment of cancer;
and SON-3015, a bi-specific combination of anti-IL6 and anti-tumor growth factor beta for tumor and bone metastases.
Sonnet BioTherapeutics Holdings, Inc. is based in Princeton, New Jersey.
News 
Market Data 
Discover 
